晚期卵巢癌新辅助化疗部分缓解或疾病稳定后的手术时机
本研究回顾性纳入265例晚期高级别卵巢癌患者,均接受至少3周期新辅助化疗及间歇性肿瘤减灭术,且疗效为部分缓解或疾病稳定。分析显示,超过4周期化疗未显著影响生存,而术后任何残留病灶均与更差的无进展生存和总生存相关。结论提示应优先考虑能否达到完全肉眼无残留。
要点
- 超过4周期新辅助化疗未显著改善或恶化生存。
- 术后任何残留病灶均与更差的无进展生存和总生存相关。
- 手术时机决策应优先考虑能否达到完全肉眼无残留。
核心结论
- 在部分缓解或疾病稳定的晚期高级别卵巢癌患者中,无论新辅助化疗周期数多少,残留病灶均与更差的生存相关。
- 能否达到完全肉眼无残留应优先于化疗周期数用于手术时机决策。
研究设计与样本
- 回顾性队列研究,纳入2013年2月1日至2018年2月1日诊断的265例晚期高级别卵巢癌患者。
- 患者接受至少3周期新辅助化疗及间歇性肿瘤减灭术,且疗效为部分缓解或疾病稳定。
- 按化疗周期数(3-4周期或>4周期)和残留病灶状态(完全肉眼无残留或任何残留)分为四组。
主要发现
- 中位诊断年龄65岁,87%为白人,89%为浆液性组织学,57%为IV期,总体完全肉眼无残留率为81%。
- 多因素分析中,>4周期化疗与3-4周期相比,无进展生存的调整风险比为1.02(95%CI 0.74-1.42),总生存的调整风险比为1.12(95%CI 0.73-1.72)。
- 任何残留病灶均与更差的无进展生存相关(调整风险比1.56,95%CI 1.09-2.22)和更差的总生存相关(调整风险比2.38,95%CI 1.52-3.72)。
临床怎么用
- 对于新辅助化疗后部分缓解或疾病稳定的晚期高级别卵巢癌患者,手术决策应优先评估能否达到完全肉眼无残留,而非单纯延长化疗周期数。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 样本以白人、浆液性组织学、IV期患者为主,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The ideal number of neoadjuvant chemotherapy (NACT) cycles prior to interval tumor-reductive surgery (iTRS) for advanced ovarian cancer is poorly defined. We sought to assess survival stratified by number of NACT cycles and residual disease following iTRS in patients with advanced ovarian cancer with partial response (PR) or stable disease (SD) following 3-4 cycles of NACT. METHODS: We retrospectively identified patients with advanced high-grade ovarian cancer (diagnosed 2/1/2013 to 2/1/2018) who received at least 3 cycles of NACT and iTRS and had a PR or SD. The population was divided into four groups based on the number of NACT cycles prior to iTRS and residual disease status after (CGR [complete gross residual] or incomplete resection [any amount of residual disease]): 1) 3-4 NACT cycles/CGR, 2) 3-4 NACT cycles/incomplete resection, 3) > 4 cycles/CGR, and 4) >4 cycles/incomplete resection. Overall survival (OS) and progression-free survival (PFS) were estimated using a Kaplan-Meier product-limit estimator and modeled using univariable and multivariable Cox proportional hazards analysis. RESULTS: The cohort consisted of 265 patients with advanced high-grade ovarian cancer with a median age at diagnosis of 65 years. Most were White (87%), had serous histology (89%), and stage IV disease (57%), with an overall CGR rate of 81%. In a multivariable analysis receipt of >4 NACT cycles was not associated with worse PFS or OS (adjusted hazard ratio [aHR] 1.02, 95% CI 0.74-1.42; aHR 1.12, 95% CI, 0.73-1.72 respectively) than was receipt of 3-4 cycles. Any amount of residual disease was associated with worse PFS and OS regardless of the number of NACT cycles (aHR 1.56, 95% CI 1.09-2.22; aHR 2.38, 95% CI 1.52-3.72 respectively). CONCLUSIONS: Residual disease was associated with worse survival outcomes regardless of the number of NACT cycles in patients with PR or SD after NACT for advanced high-grade ovarian cancer. These data suggest that the ability to achieve CGR should take precedence in decision-making regarding the timing of surgery.
引用
- Nitecki R, Fleming ND, Fellman BM, et al. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2021. PMID: 33867146. doi:10.1016/j.ygyno.2021.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。